Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results from a Pragmatic Cluster-Randomized Clinical Trial

Clicks: 24
ID: 326847
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #114 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Influenza outbreaks in U.S. nursing homes contribute substantially to morbidity, mortality, and operational strain. Recombinant influenza vaccine may reduce transmission in long-term care settings, but high-quality evidence to support this effect is limited. To compare the risk of influenza outbreaks (confirmed outbreak: 1+ laboratory-confirmed cases; suspected outbreak 2+ influenza-like illness cases) among nursing homes randomized to recombinant quadrivalent influenza vaccine (RIV4) versus standard-dose egg-based inactivated quadrivalent influenza vaccine (IIV4). Methods This study was a pragmatic, cluster-randomized clinical trial conducted across two influenza seasons (n=965 facilities 2019–2020 and n=1,023 in 2020–2021) in Medicare-certified U.S. nursing homes. Nursing homes with ≥50 long-stay residents and high proportions of adults aged ≥65 years were eligible and assigned to RIV4 or IIV4 for resident and staff vaccination. The outcome was facility-reported influenza outbreaks, assessed by monthly logs. Results During the 2019–2020 season, RIV4-assigned facilities experienced fewer suspected (148 [30.6%] vs 178 [37.0%]) and laboratory-confirmed (177 [36.6%] vs 214 [44.5%]) influenza outbreaks than IIV4 facilities. The adjusted relative risk (RR) for confirmed outbreaks was 0.82 (95% Confidence Interval, 0.71–0.96). In 2020–2021, confirmed outbreaks were rare (16 vs 15), and no significant differences were observed. COVID-19 outbreak risk did not differ between groups in either season. Conclusions RIV4 reduced influenza outbreak occurrence in U.S. nursing homes during a season with moderate influenza activity in older adults. No differences were observed during the low-circulation 2020–2021 season. These findings suggest that recombinant influenza vaccines may provide clinically meaningful facility-level benefits in long-term care settings during seasons with substantial influenza circulation.
Reference Key
openalex_W7204455912 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kevin W. McConeghy, H. Edward Davidson, Lisa Han, David H. Canaday, Yasin Abul, Kaleen N. Hayes, Stefan Gravenstein
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag522
URL
https://doi.org/10.1093/ofid/ofag522
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.